Dubai, UAE – In a move that could make it the first company from outside the Gulf region to list its shares on a regional stock exchange. Hong Kong-listed biotechnology company Insilico Medicine Cayman Top Co is studying the possibility of implementing a secondary listing on the Abu Dhabi Securities Exchange.
Sources said the company, which listed on the Hong Kong Stock Exchange last December, had held preliminary discussions about listing on the Abu Dhabi Stock Exchange, possibly as early as this year. Noting that the talks are still in their preliminary stages.
According to the sources, the deal is initially designed in the form of a direct listing. With the possibility of the company’s shareholders later moving to raise additional capital through the market. She also noted that a number of investors based in Abu Dhabi participated in the company’s initial public offering in Hong Kong.
Existing relations with the UAE
Insilico Medicine has raised $337 million since its initial public offering last December. Its share price has doubled since then.
There was no official comment from company representatives or the Abu Dhabi Securities Market regarding these potential plans.
In contrast, data showed that stock sales in Hong Kong have exceeded $20 billion since the beginning of this year. Compared to $3.2 billion during the same period in 2025.
The company, which relies on artificial intelligence technologies to discover medicines, has existing ties with the UAE. After announcing earlier this year a partnership with government-backed entities.
This trend reflects harmony with the UAE’s economic diversification strategy, which places the artificial intelligence and healthcare sectors among its main priorities. At a time when Abu Dhabi continues its efforts to attract startups and advanced technologies
